President Donald Trump has announced a major deal with Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their blockbuster obesity drugs, Zepbound and Wegovy. These GLP-1 treatments, known for their effectiveness in weight loss, have been out of reach for many Americans due to high costs and limited insurance coverage. Starting next year, Medicare will cover the drugs, and new lower-priced pill versions could cost as little as $149 a month. The move marks Trump’s latest push to tackle rising healthcare costs and inflation concerns. Will this reshape America’s health landscape?